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 The SARS-CoV-2 (COVID-19) virus causes a wide spectrum of disease in healthy individuals as well 
as those with common comorbidities (1). Severe COVID-19 is characterised acute respiratory distress 
syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical 
ventilation or extracorporeal membrane oxygenation (ECMO) (2). Clinicians are alert to the possibility 
of bacterial co-infection as a complication of lower respiratory tract viral infection; for example a recent 
review found that 72% of patients with COVID-19 received antimicrobial therapy (3). However, the risk 
of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains 
underappreciated. 
 
Fungal disease consistent with invasive aspergillosis (IA) has been observed with other severe 
Coronaviruses such as Severe Acute Respiratory Syndrome (SARS-CoV-2003) (4, 5) and Middle 
East Respiratory Syndrome (MERS-CoV) (6). From the outset of the COVID-19 pandemic, there were 
warning signs of secondary invasive fungal infection; Aspergillus flavus was isolated from the 
respiratory tract from one of 99 patients in the first COVID-19 cohort from Wuhan to be reported in 
any detail (2) and Aspergillus spp. were isolated from 2/52 (3.8%) of a subsequent cohort of critically 
unwell patients from this region (7). More recently, retrospective case series from Belgium (8), France 
(9), The Netherlands (10)  and Germany (11) have reported evidence of CAPA in an alarming 20-35% 
of mechanically ventilated patients.  
 
Coronavirus-associated pulmonary aspergillosis (CAPA) 
Influenza-associated pulmonary aspergillosis (IAPA) presents a known risk to critically unwell patients 
with influenza (12-14) and the clinical course of COVID-19 shows many features that are shared with 
severe influenza infection. These include ARDS, lymphopenia, bilateral pulmonary infiltrates, systemic 
pro-inflammatory cytokine responses and sepsis leading to multiple organ failure (14, 15). It is 
therefore reasonable to suspect that patients with severe COVID-19 may be similarly susceptible to 
IA. Corticosteroid use is an important acquired immunological risk factor for IAPA (16) and, during the 
SARS-2003 epidemic, there were case reports of patients developing SARS-associated IA after 
corticosteroid use (5). Corticosteroid use has been reported in hospitalised patients with COVID-19 
(1) and may further contribute to the risk of CAPA. Importantly, the recent finding by the UK 
RECOVERY trial (ISRCTN50189673) (17) of a one- third mortality reduction conferred by 
 dexamethasone in ventilated patients with Covid-19, while leading to a crucial new therapeutic 
avenue, may increase the risk of patients acquiring CAPA and emphasises the need for enhanced 
fungal surveillance. 
 
Table 1 summarises individual patient-level data in 33 cases of CAPA that have been reported to 
date. The median age of cases is 70 (IQR 57-75), of whom only 2 (6%) had an EORTC host factor. Of 
these 16 (48%) had exposure to inhaled or systemic corticosteroids, 10 (30%) diabetes and 9 (27%) 
underlying chronic lung disease; chronic obstructive pulmonary disease (n=5), asthma (n=3), bullous 
emphysema (n=1), pulmonary fibrosis (n=1) and post-radiotherapy for non-small-cell lung cancer 
(n=1). CAPA was diagnosed a median 5.5 days (IQR 4.3-9) after ICU admission and 21 (63.6%) of 
patients had died at the time of publication. This mortality is in excess of most cohorts of ventilated 
patients with COVID-19, as a comparison in the UK ISARIC cohort 618/1658 (37%) of ventilated 
patients had died by the time of publication (17% discharged and 46% still receiving care) (18).  
 
IA is difficult to diagnose in critically unwell patients without traditional host factors because 
radiological changes are usually non-specific (e.g. infiltrates, consolidation or nodules), with features 
such as halo sign, air-crescent sign or cavitation being rare (19). For these reasons Schauwvlieghe et 
al. developed the modified AspICU criteria to help diagnose IAPA which (in the absence of histology) 
essentially relies on mycological evidence of Aspergillus spp. in the form of a positive bronchoalveolar 
lavage (BAL) culture or positive galactomannan (GM) in serum/BAL. Applying these modified AspICU 
criteria (13), five cases of CAPA in Table 1 were ‘proven’, 11 ‘putative’ and 17 might be considered 
putative but with caveats which have been described in the table. For example, in many cases a 
tracheal aspirate, rather than BAL, provided the only mycological evidence of IA (in the absence of 
tracheobronchitis/cavitation). There should therefore be caution about over-estimating the incidence 
of CAPA from such case series, which may include some patients with Aspergillus colonisation or 
contamination only. In the study by Alanio et al. (9) which reported evidence of CAPA in 9/27 (33%) of 
ventilated patients who underwent BAL/ tracheal aspirate (TA), one case was defined based on on a 
BAL GM of 0.89 (below the usual cut-off of 1.0), two based on TA rather than BAL culture, one based 
on a serum GM of 0.51 (cut-off being 0.50) and in four cases BAL culture was positive but BAL GM 
negative, which suggests a lack of tissue invasion. Indeed, of seven cases that were not treated with 
 antifungals, five survived. Accordingly, larger, prospective, multi-site studies are needed to refine the 
AspICU criteria for patients with COVID-19, as well as to estimate incidence and the impact of CAPA 
on survival (20, 21). 
 
Diagnosis and risk of CAPA 
Bearing these observations in mind, we argue that critically ill patients with COVID-19 and 
progressive features should be screened for CAPA. We acknowledge that acquiring and handling 
clinical samples for microbiology is very challenging given the Hazard Group 3 (HG3) rating of the 
SARS-CoV-2 virus, alongside an overburdened critical care service (22).  
 
Ideally, screening for CAPA entails using a combination of CT chest imaging and Aspergillus antigen 
tests on BAL and serum including galactomannan (GM) ELISA or lateral-flow tests (23), or Aspergillus 
PCR  (24). Whilst characteristic CT features of IA such as nodules with halo sign were seen in 17.6% 
of severely ill COVID-19 patients, they were not confirmed to be IPA (25). Given the lack of typical IA 
features on CT in IAPA, the absence of classical findings such as cavitation should not be used to 
exclude CAPA, however their presence can help support the diagnosis and reduce the burden of 
evidence placed on mycological investigations. 
 
In a study of 26 ICU patients that were diagnosed with proven (non-CAPA/IAPA) IPA post-mortem, 
serum GM had only 25% sensitivity in those that were not neutropenic (vs 70% in neutropenic 
patients)  (26). In contrast, BAL GM was 88-90% sensitive in both groups. In the IAPA study by 
Schauwvlieghe et al. (13) serum GM testing performed better with 20/31 (65%) of cases positive, 
however BAL GM remained superior at 67/76 (88%). In CAPA cases reported to date (Table 1), BAL 
culture and GM had a sensitivity of 72.7% and 66.7% respectively, but serum GM was positive in only 
6/28 (21.4%). Moreover, of the five cases of proven CAPA reported to date, four were serum GM 
negative [Table 1; (8)], indicating that serum GM test performance might be inferior in diagnosing 
CAPA. Therefore, bronchoscopy, including tracheobronchial inspection and BAL sampling for culture 
and GM should be the diagnostic gold standards whenever CAPA is suspected, providing this is 
compatible with local infection prevention and control guidance for aerosol-generating procedures. A 
positive BAL GM (index >1.0) would be indicative of CAPA, whereas if the index is <0.5, CAPA is 
 much less likely (26). A positive serum GM result (≥ 0.5) would be highly suspicious for CAPA but a 
negative result should not be used to exclude the diagnosis. Novel lateral-flow antigen tests may 
represent a locally implementable alternative to GM ELISA in the CL3 laboratory, but currently require 
validation in ICU patients without EORTC host factors including COVID-19 (23). An Aspergillus-
specific PCR test (24) may also be helpful and if positive could also lead to the application of 
molecular testing for the recognised markers of clinically or environmentally-derived azole-resistance 
(27).  
 
A (1-3)-β-D-glucan (BDG) test on a serum sample is an easily obtained, early screening test when 
there is a suspicion of IPA. Although performance might be superior to serum Aspergillus antigen 
testing for the detection of IPA in the ICU (28), BDG negativity cannot be used to rule out infection, 
with a 77% sensitivity determined across a heterogeneous population of IA patients, and performance 
in CAPA as yet to be determined. BDG positivity can occur due to a number of reasons in this patient 
cohort, however serial positive tests increases specificity and should prompt a diagnostic work-up 
including CT and bronchoscopy and testing for Aspergillus antigen as outlined above (29). While 
initiating antifungal treatment pre-emptively based on of BDG positivity may be an improvement on 
empirical therapy, every effort should be made to utilise other more specific diagnostic tests to 
complement the BDG result.  
 
Current guidelines advise against routine diagnostic bronchoscopy due to the risk of aerosol 
generation; recommending it only in patients in whom nasopharyngeal cultures are negative and BAL 
sampling will change clinical management (30). In practice many patients with suspected CAPA 
undergo endotracheal sampling or non-directed BAL sampling only, and it is important that any case 
definition proposed for CAPA reflects this reality. To acknowledge this, we  propose a screening and 
diagnostic algorithm for CAPA, which has clinical (respiratory) deterioration and/or positive Aspergillus 
sputum, or tracheal aspirate culture as its entry point (Figure 1). Although the host risk factors and 
clinical characteristics of CAPA are not yet understood, those individuals fulfilling the criteria for 
proven or probable aspergillosis (13, 14) should then be treated according to current guidelines (31, 
32). Importantly, now that adjunctive use of dexamethasone is likely to become widespread in the 
 treatment of patients with severe Covid-19 (17), intensified screening for IA is indicated to study the 
possible association between corticosteroid usage and CAPA.  
 
Finally, the use of immunomodulatory drugs such as Anakinra (recombinant IL-1Ra), Tocilizumab 
(anti-IL6) and Janus kinase (JAK) inhibitors, currently undergoing trials for COVID19, may also 
predispose patients to CAPA.  There is also an increased risk of Aspergillus exposure for patients 
who are treated in hospital wards or makeshift ‘hospital’ facilities that do not meet ICU specifications 
for appropriate room ventilation and air changes. It is also worth bearing in mind that pulmonary 
aspergillosis could develop into a chronic cavitary disease in a subset of patients, perhaps in those 
developing post-COVID19 pulmonary fibrosis. For these reasons, clinicians following up patients 
manifesting chronic respiratory problems following their primary COVID-19 infection should bear in 
mind longer-term fungal complications. 
 
Conclusions 
Fungal infections present an additional threat in the challenging task of managing COVID-19 patients 
in outbreak conditions. The pandemic of SARS-CoV-2 virus will undoubtedly involve CAPA, and the 
use of immunomodulatory therapy and impact of overburdened critical care services during this 
pandemic may exaggerate its impact. More research is needed on the epidemiology and diagnosis of 
CAPA in patients with COVID-19, a need that is partially met as ongoing prospective multi-site clinical 
studies are extended to include this cohort (e.g. AspiFlu (20)) or are launched (CAPA (21)) in 
response to pandemic COVID-19. 
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 Table 1. Summary of reported cases of COVID-19 associated pulmonary aspergillosis (CAPA) 
Setting [ref] Age Sex IA risk factors Radiology 
BAL 
culture TA culture BAL GM Serum GM Other diagnostics 
Onset 
days 
post 
ICU EORTC status 
Mod AspICU 
status Treatment Outcome 
ICU, Cologne, 
Germany [1] 62 F 
Ex smoker, moderate 
COPD, inhaled steroids 
Ground-glass opacities, crazy paving, 
peripheral nodular consolidation 
A. 
fumigatus NR (+) >2.5 (-) BAL PCR A. fumigatus NR No host factor
a
 Putative V Died 
ICU, Cologne, 
Germany [1] 70 M Ex smoker 
Ground-glass opacities, occasional 
nodules (-) NR (+) >2.5 (+) 0.7 BAL PCR A. fumigatus NR No host factor Putative I  Died 
ICU, Cologne, 
Germany [1] 54 M 
Diabetes, systemic 
corticosteroids 0.4 
mg/kg/d x 13 days 
Ground-glass opacities, nodular 
infiltrates with cavities, air crescent 
sign (-) 
A. 
fumigatus (+) >2.5 (-) BAL PCR A. fumigatus NR No host factor Putative C, V  Alive 
ICU, Cologne, 
Germany [1] 73 M 
Smoker, bullous 
emphysema, severe 
COPD, inhaled steroids 
Ground-glass opacities, occasional 
nodules, known bullous emphysema ND 
A. 
fumigatus ND (-) TA PCR A. fumigatus NR No host factor 
Putative only if TA 
considered 
equivalent to BAL V Died 
ICU, Cologne, 
Germany [1] 54 F None 
Ground-glass opacities, crazy paving, 
central and peripheral consolidation, 
smaller nodular infiltrates ND (-) ND (+) 2.7, 1.3 TA PCR (-) NR No host factor Putative C, V Alive 
ICU, Munich, 
Germany [2] 80 M Pulmonary fibrosis 
"typical signs for COVID-19 
pneumonia but no specific signs for 
IPA" 
A. 
fumigatus NR (+) >6 (+) 1.5 
 
5 No host factor Putative L-AmB Died 
ICU, Munich, 
Germany [2] 70 M None 
"typical signs for COVID-19 
pneumonia but no specific signs for 
IPA" 
A. 
fumigatus NR (+) >6 (-) 
 
6 No host factor Putative L-AmB Died 
ICU, Paris, 
France [3] 74 M 
Myelodysplastic 
syndrome NR ND 
A. 
fumigatus ND (-) x2 
TA PCR A. fumigatus 
x2, TA GM (-) x 1, BDG 
and serum PCR (-) x2 4 No host factor 
Putative only if TA 
considered 
equivalent to BAL None Died 
ICU, Paris, 
France [4] 53 M 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 "Typical COVID-19" (-) NR (-) 0.89 (-) 
BAL PCR (-), Serum 
PCR: (-), BDG (+) > 
500 NR No host factor 
Putative only if BAL 
GM cut-off lowered 
to > 0.8 None Alive 
ICU, Paris, 
France [4] 59 F Diabetes "Typical COVID-19" 
A. 
fumigatus NR (-) (-) 
BAL PCR (-), Serum 
PCR (-) NR No host factor 
Putative but note 
BAL culture (+) but 
BAL GM (-) None Alive 
ICU, Paris, 
France [4] 69 F 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 "Typical COVID-19" ND 
A. 
fumigatus ND (-) 
TA PCR A. fumigatus, 
Serum PCR (-), BDG (-) NR No host factor 
Putative only if TA 
considered 
equivalent to BAL None Alive 
ICU, Paris, 
France [4] 63 F 
Diabetes, 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 "Typical COVID-19" (-) NR (-) (+) 0.51 
BAL PCR (-), BDG (+) 
105 NR No host factor 
Putative but relies 
on serum GM of 
only 0.51 None Died 
ICU, Paris, 
France [4] 43 M Asthma, corticosteroids "Typical COVID-19" 
A. 
fumigatus NR (-) (-) 
BAL PCR (-), Serum 
PCR (-), BDG (-) NR No host factor 
Putative but note 
BAL culture (+) but 
BAL GM (-) None Alive 
ICU, Paris, 
France [4] 79 M 
Diabetes, 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 
"Typical COVID-19", segmental lung 
atelectasis 
A. 
fumigatus NR (-) (-) 
BAL PCR A. fumigatus, 
Serum PCR (-), BDG (-) NR No host factor 
Putative but note 
BAL culture (+) but 
BAL GM (-) None Alive 
ICU, Paris, 
France [4] 77 M 
Asthma, 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 "Typical COVID-19", emphysema 
A. 
fumigatus NR (+) 3.9 (-) 
BAL PCR A. fumigatus, 
Serum PCR (-), BDG 
(+) 135 NR No host factor Putative V Died 
ICU, Paris, 
France [4] 75 F 
Diabetes, 
Dexamethasone 
20mg/d days 1-5, 
10mg/d days 6-10 "Typical COVID-19" 
A. 
fumigatus NR (-) (-) 
BAL PCR, A. 
fumigatus, Serum PCR 
(-), BDG (+) 450 NR No host factor 
Putative but note 
BAL culture (+) but 
BAL GM (-) C Died 
ICU, Paris, 
France [4] 47 M 
Myeloma, 
corticosteroids 
"Typical COVID-19", one peripheral 
nodule ND 
A. 
fumigatus ND (-) 
TA PCR A. fumigatus, 
Serum PCR (-), BDG (-) NR Probable 
Putative only if TA 
considered 
equivalent to BAL None Died 
ICU, Graz, 
Austria [5] 70 M 
Moderate COPD, 
steroid inhaler, 
obstructive sleep 
apnoea, diabetes 
Ground-glass opacities, crazy paving, 
reversed halo sign. Progression of the 
bilateral infiltrates on day 2 CXR. ND 
A. 
fumigatus ND (-) TA LFD (+), BDG (-) 3 No host factor 
Putative only if TA 
considered 
equivalent to BAL V Died 
ICU, Antwerp, 
Belgium [6] 86 M None ND ND A. flavus ND (-) 
 
9 No host factor 
Putative only if TA 
considered None Died 
 equivalent to BAL 
ICU, Antwerp, 
Belgium [6] 38 M None "(+)" 
A. 
fumigatus NR (+) > 2.8 (-) 
Histology from 
bronchoscopy (+) 6 Proven Proven V, I Alive 
ICU, Antwerp, 
Belgium [6] 62 M Diabetes  ND 
A. 
fumigatus NR (+) > 2.0 (-) 
Histology from 
bronchoscopy (+) 16 Proven Proven V Died 
ICU, Antwerp, 
Belgium [6] 73 M Diabetes  ND 
A. 
fumigatus NR (+) > 2.8 (-) 
Histology from 
bronchoscopy (+) 5 Proven Proven V Alive 
ICU, Antwerp, 
Belgium [6] 77 M 
Diabetes, chronic 
corticosteroids for 
pemphigus foliaceous ND 
A. 
fumigatus NR (+) 2.79 (-) 
Histology from 
bronchoscopy (+) 2 Proven Proven V Alive 
ICU, Antwerp, 
Belgium [6] 55 M 
HIV (CD4 count > 250, 
viral load < 20) 
copies). ND (-) NR (-) (+) 0.8 
Histology from 
bronchoscopy (-) 13 No host factor 
Putative but relies 
on serum GM of 
only 0.8 V, I Died 
ICU, Antwerp, 
Belgium [6] 75 M AML with IPA 2012 ND 
A. 
fumigatus NR (+) 2.63 ND 
 
8 No host factor Putative V Died 
ICU, Breda, 
The 
Netherlands [7] 83 M 
Prednisolone 0.13 
mg/kg/d x 28 days for 
cardiomyopathy NR ND 
A. 
fumigatus ND (-) 
 
3 
Probable if 
steroid 
requirement 
reduced to < 
0.3mg/kg/d 
Putative only if TA 
considered 
equivalent to BAL 
V + A, or 
L-AmB Died 
ICU, Breda, 
The 
Netherlands [7] 67 M 
Severe COPD, Post RT 
for NSCLC 2014, 
Prednisolone 0.37 
mg/kg/d x 2 days NR ND 
A. 
fumigatus ND ND  3 No host factor 
Putative only if TA 
considered 
equivalent to BAL 
V + A, or 
L-AmB Died 
ICU, Breda, 
The 
Netherlands [7] 75 M Moderate COPD NR 
A. 
fumigatus NR (+) 4.0 ND 
Mucoid white sputum 
left bronchus at 
bronchoscopy 5 No host factor Putative 
V + A, or 
L-AmB Died 
ICU, Breda, 
The 
Netherlands [7] 43 M None NR (-) NR (+) 3.8 (-) 
 
14 No host factor Putative 
V + A, or 
L-AmB Alive 
ICU, Breda, 
The 
Netherlands [7] 57 M 
Asthma, inhaled 
steroids NR 
A. 
fumigatus NR (+) 1.6 (-) 
 
5 No host factor Putative 
V + A, or 
L-AmB Died 
ICU, Breda, 
The 
Netherlands [7] 58 M None NR ND 
A. 
fumigatus ND ND 
 
28 No host factor 
Putative only if TA 
considered 
equivalent to BAL 
V + A, or 
L-AmB Alive 
ICU, Paris, 
France [8] 80 M None 
Pleural effusions, alveolar 
condensation, ground-glass opacities, 
pulmonary cysts ND A. flavus ND ND 
 
NR No host factor 
Putative only if TA 
considered 
equivalent to BAL V, I Died 
ICU, Milan, Italy 
[9] 73 M Diabetes 
Interstitial opacities with right upper 
lobe focal consolidation which 
progressively worsened  
A. 
fumigatus NR ND (+) 8.6 
Lung histology from PM 
(+), PM tissue PCR 
Aspergillus spp 9 Proven Proven L-AmB Died 
Summary 
Medi
an 
(IQR
) 
N = 
M 
(%)  Of the 19 with details reported 
Of the 22 
with BAL n 
= (+), (%)  
Of the 
21 with 
BAL GM 
n = (+), 
(%) 
Of the 28 
with serum 
GM n = (+), 
(%)  
Median 
(IQR)   
N = 
treated 
(%) N = died (%) 
 
70 
(57-
75) 
26/
33 
(79)  
EORTC Host factor 
2(6%), inhaled/systemic 
steroid exposure 
16(48%), diabetes 
10(30%), chronic lung 
disease 9(27%)  
Nodules 6 (31.6%), cavity/ halo-sign 2  
(10.5%) 16 (72.7) 
 
14 (66.7) 6 (21.4) 
 
5.5 
(4.3-9) 
Proven (5), 
Probable (1), 
No host factor 
(27) 
Proven (5), 
Putative (11), 
Putative with 
caveats (17) 24 (72.7) 21 (63.6) 
A, Anidulafungin. BAL, Bronchoalveolar lavage. BDG, Beta-d-glucan. C, Caspofungin. GM, Galactomannan. IA, Invasive Aspergillosis. I, Isavuconazole. L-AmB, Liposomal Amphotericin B. LFD, Aspergillus lateral-flow device. NSCLC, non-small-cell lung cancer. RT, radiotherapy. PCR 
Polymerase chain reaction. PM, post-mortem. TA, Tracheal Aspirate. V, Voriconazole. EORTC, Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer. BAL GM (+) ≥1.0, Serum GM (+) ≥ 0.5. 
a. Under EORTC criteria without histological evidence of ‘proven’ IPA a patient host factor (e.g. recent neutropenia, haematological malignancy) is required to meet the ‘probable’/’possible’ definition. Corticosteroids must be given at ≥0.3 mg/kg for ≥3 weeks to classify as a host 
factor. 
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 Figure 1: Proposed screening and diagnostic algorithm for COVID-19 Associated Pulmonary Aspergillosis (CAPA)  
 
 
Notes: BAL- Bronchoalveolar lavage; BDG- (1-3)-β-D-glucan; TA- tracheal aspirate; Aspergillus antigen (Asp Ag)- GM ELISA or lateral-flow antigen; AF- 
Antifungal 
CAPA highly likely
Serum biomarker 
(Asp Ag; PCR; BDG)
≥1 Positive
AF therapy
CAPA likely
Serum biomarker 
(Asp Ag; PCR; BDG)
Negative
BAL Aspergillus
(Antigen; culture; PCR)
≥1 Positive
Serum biomarker 
(Asp Ag; PCR; BDG)
≥1 Positive
BAL Aspergillus
(Antigen; culture; PCR)
Negative
Serum biomarker 
(Asp Ag; PCR; BDG)
≥1 Positive
BAL not possible
CAPA not excluded
Serum biomarker 
(Asp Ag; PCR; BDG)
≥1 Negative
Consider AF therapy taking into consideration: 
• Underlying EORTC host factors
• Risk factors (co-infection with influenza; corticosteroids/other 
immunomodulators)
• Clinical deterioration with no other explanation
• New nodules with cavitation or halo sign or consolidation
• Follow-up serum biomarker results
• Progressive pulmonary infiltrates
Trigger:
• Microbiological - Sputum / TA  Aspergillus culture positive
• Clinical: - Deteriorating or persistent poor respiratory function 
with no other explanation, or progressive radiology
Considerations: 
• If BAL not possible, consider NBL
• BDG may be more sensitive than serum GM
• BDG is not specific for IA, also consider candidiasis or PCP
• Very high BAL GM index (>3) suggestive of CAPA
• Biomarker test combinations may be superior compared to single 
tests
• Serum biomarker negativity in the absence 
of BAL testing does not exclude IA
CAPA unlikely
Serum biomarker 
(Asp Ag; PCR; BDG)
≥1 Negative
No AF therapy
CAPA likely CAPA likely
